Background. Reversal of neuromuscular block can be accomplished by chemical encapsulation of rocuronium by sugammadex (Org 25969), a synthetic g-cyclodextrin derivative. The present study determined the time course of the reversal action of sugammadex on rocuronium-induced block in the anaesthetized Rhesus monkey using train-of-four stimulation.
The mechanism, encapsulation of the rocuronium molecule, results in a rapid decrease in its free plasma concentration and its removal from the motor endplates, resulting in the reappearance of muscle activity.
1 Sugammadex is highly water-soluble and has no direct or indirect action on components of cholinergic transmission (acetyl-cholinesterase, nicotinic receptors or muscarinic receptors), and therefore it is unlikely that muscarinic side effects will occur.
1 Recent studies in Rhesus monkeys and humans have shown that this new method of reversing the neuromuscular effects of rocuronium is fast, efficient and lacks the well-known undesirable side effects associated with the use of a combined cholinesterase inhibitor and muscarinic antagonists. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, no reports of the time course of action of sugammadex have been published so far. This information may be important if a further dose of rocuronium is needed to re-establish neuromuscular block. The capability of re-establishment of neuromuscular block by rocuronium after reversal with sugammadex is therefore unknown.
The present study was designed to evaluate the time course of action of sugammadex in Rhesus monkeys. The reversal capacity of a single bolus injection of sugammadex (1.0 mg kg À1 ) as a function of time was evaluated by its blocking effect on a fixed dose of rocuronium (100 mg kg À1 ) before and 15, 30 and 60 min after administration. The experiments were performed with trainof-four (TOF) stimulation. A model is used, based on the equilibrium of complex formation of rocuronium and sugammadex, to solve the residual amount of sugammadex as a function of time from the observed maximum blocks.
Methods
These in vivo experiments were performed in the experimental laboratories of the Department of Anaesthesiology at the Radboud University Medical Centre in Nijmegen, The Netherlands. The experiments were approved by the regional ethical committee on animal experiments. Four female Rhesus monkeys (CSIMS, Beijing, China) were studied. They were sedated with ketamine 10 mg kg À1 (Nimatek Eurovet) administered by i.m. injection. Two i.v. lines were sited, one for anaesthetic administration, including rocuronium, and the other for test drug administration. This was followed by i.v. injection of pentobarbital sodium (Ceva Sante Animale), 25 mg kg À1 , and a subsequent continuous infusion of 5-10 mg kg À1 h À1 . The monkeys were intubated endotracheally and the lungs ventilated with a mixture of oxygen and nitrous oxide in a ratio of 2:3. Heart rate and oxygen saturation were determined at the ear with a pulsoximeter (Ohmeda, Biox). Blood pressure was determined with a cuff placed around the tail (Finapres, Ohmeda). Body temperature was measured by a rectal probe and maintained at 37-38 C. For monitoring purposes the median nerve of the right arm was supramaximally stimulated near the wrist using needle electrodes. Stimulation was performed with 2 ms square wave pulses in a TOF sequence of 2 Hz with an interval of 15 s delivered by a Grass S88 Stimulator (Grass Medical Instruments, Quincy, MA, USA). The resulting contractions of the thumb muscles were quantified with a force displacement transducer and recorded on a polygraph. After an initial i.v. bolus injection of rocuronium bromide 100 mg kg À1 (approximately ED 90 value for our Rhesus monkey population) the preparation was allowed to recover spontaneously. Sixty minutes after a complete steady-state spontaneous recovery, sugammadex 1.0 mg kg À1 was given intravenously as a rapid bolus. Then another i.v. bolus injection of rocuronium 100 mg kg À1 (the same dose as the first injection) was given 15, 30 or 60 min after the administration of sugammadex (in each of the four animals the three different time intervals were applied in a series of three different experiments; a total of 12 experiments; the actual order of time intervals were 60, 15 and 30 min). To evaluate which time intervals were necessary to cover enough of the elimination of sugammadex, the first experiment was performed with a time interval of 60 min. From the experimental traces T1 and TOF-ratio recovery times were calculated at 25, 50, 75 and 90% recovery, with respect to the basic value. The maximal degree of neuromuscular block obtained, the onset time of this maximal neuromuscular block, and neuromuscular recovery times of this neuromuscular block induced by rocuronium 100 mg kg À1 before and 15, 30, or 60 min after the injection of sugammadex were calculated from the traces. Only the maximum block values were used for further analysis of the half-life of sugammadex. At the end of the experiments, the animals were allowed to recover from anaesthesia.
Model description
A model to describe the expected block as a function of rocuronium dose of D roc mg kg À1 , t minutes after the injection of a dose of sugammadex D sugammadex mg kg À1 , can be obtained with the following assumptions: 
The amount of available sugammadex as a function of time follows a first order exponential decay:
The procedure of estimating half-life, using the above model, is outlined: The parameters ED 50 and g in the Hill equation:
50 Þ are determined as follows: g follows from the dose-response relationship in our monkey population: g=5. ED 50 in each individual experiment then follows by solving the Hill relationship.
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The complex equilibrium constant:
where D expressed in mol kg À1 , is calculated from the situation that a rocuronium dose of half of the ED 50 only provides for a few percentage of block. This block depth is also approximately obtained by an ED 90 rocuronium dose given simultaneously with sugammadex 1.0 mg kg À1 . Therefore, the free rocuronium concentration must be almost equal in both situations. The free fraction of rocuronium in the latter situation then follows to be about 0.3. All three factors in K 0 can then be calculated from the dosages and molecular weights of sugammadex (2178) and rocuronium (609), with the result of K=6.6·10 6 kg mol À1 . Given the exponential decay of total sugammadex, D=D 0 ·e (Àk·t) , the free fraction of injected rocuronium can be predicted from this decay and the equilibrium constant K 0 . The free fraction can also be calculated from the injected dose, the individually obtained ED 50 and the measured T1 block because of the second rocuronium injection. The least squares fitting procedure minimizes the differences between these two results of the free fraction by adapting the time constant in the exponential decay relationship.
The same procedure is applicable to TOF-ratios. The main difference is that the parameters of the Hill equation, ED 50 and g, are slightly different. However, at profound block, when both T1 and T4 are very small, TOF-ratios become very inaccurate. To avoid the bias introduced by this effect, we restricted the procedure to T1 blocks.
Measurements concerning blocks and recovery times are presented as mean (SEM). Data were analysed, using a Student's t-test, P-values <0.05 were considered statistically significant.
Results
Twelve experiments were performed in which four different female Rhesus monkeys were used (weight 5.1-6.5 kg) three times each. In the three experiments on a single animal the time intervals between injection of sugammadex and rocuronium 100 mg kg À1 were 15, 30 and 60 min. Between experiments the Rhesus monkeys recovered for at least 6 weeks. The body temperature was 37.2-37. 8 C. The tracings of three experiments, in one particular monkey, are shown in Figure 1A -C. Figure 1A depicts the overlap of the T1 twitch corresponding to the calibrating 'initial dose' injections. Figure 1B and C show the overlap of tracings corresponding to the T1 twitch and TOF-ratios, respectively, as a function of the second rocuronium dose. Time course of rocuronium and the effect of sugammadex are listed in Table 1 . In Figure 2 the effect (Maximum T1 block) of rocuronium 100 mg kg À1 15, 30 and 60 min after the injection of sugammadex 1.0 mg kg À1 is shown and compared with the predicted effects as calculated in our model. The asymptotic value at the right of the S-shaped curve that predicts the effect of 100 mg kg À1 rocuronium is equal to the block value in the absence of sugammadex (the value reached by the calibrating first dose). The calculated half-life of sugammadex in Rhesus monkeys follows from a least squares fitting procedure: 30 min. Injection of sugammadex did not have significant effects on blood pressure or heart rate. All animals recovered completely without complication. Signs of residual block or recurarization in the experiments with sugammadex were not observed.
Discussion
Sugammadex, per-6-(2-carboxyethylthio)-per-6-deoxy-gcyclodextrin sodium salt, is able to form a host-guest inclusion complex with rocuronium, also known as chemical encapsulation.
1 Nuclear magnetic resonance spectroscopy and X-ray crystallography of this host-guest inclusion complex showed a tight 1:1 complex with the rocuronium molecule intercalated in the cyclodextrin ring.
1 Encapsulating the rocuronium molecule with sugammadex results in a rapid decrease in the free concentration of rocuronium in plasma and its removal from motor endplates. Rocuronium is therefore less available to bind to nicotinic receptors in the neuromuscular junction. This will promote the liberation of free acetylcholine receptors, and muscle activity will reappear. As a result of no direct or indirect action on cholinergic transmission, it is unlikely that muscarinic side effects will occur.
1 Previous studies in Rhesus monkey and humans confirmed the ability of sugammadex to reverse neuromuscular block induced by rocuronium without significant cardiovascular side effects.
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The present study showed that sugammadex at a dose of 1.0 mg kg À1 still has residual effects in plasma after 60 min and is still able to reverse the effects of neuromuscular block induced by rocuronium faster compared with spontaneous recovery. In the model presented, this means that after 60 min the exponentially decaying concentration is still above a non-effective level. In a least squares fitting procedure within this model the effective half-life of sugammadex in Rhesus monkeys 30 min (SEM=4.9 min, calculated from the results in individual monkeys) in this population of four monkeys. The half-life of sugammadex is relatively short. Despite this, recurarization has not been observed when sugammadex is given to reverse rocuronium induced neuromuscular block. However, present clinical experience with sugammadex is limited.
In theory re-establishment of rocuronium neuromuscular block is feasible only when most of the unbound sugammadex has disappeared (sugammadex is excreted rapidly and dose-dependently in urine). 10 If this is not the case, higher amounts of rocuronium will be necessary. The presented model allows the calculation of the required amount by approximation. Another possibility to re-establish neuromuscular block is the use of atracurium or mivacurium. Sugammadex has no effect on neuromuscular block induced by the non-steroidal neuromuscular blocking agents mivacurium and atracurium because the size of the cyclodextrin cavity is too small to accommodate these bulky molecules.
5
It should be emphasized that re-establishment of neuromuscular block by atracurium or mivacurium excludes the use of sugammadex for reversal of the second block.
The results of this study in Rhesus monkeys may indicate that re-establishment of rocuronium neuromuscular block is possible after reversal with sugammadex. However, further investigation is needed in humans to confirm and to extend our findings. It should be noted that when interpreting these data that the Rhesus monkey is more sensitive to rocuronium compared with humans (ED 90 in humans is about 300 mg kg À1 ; in Rhesus monkeys ED 90 is approximately 100 mg kg À1 ). Another obvious difference between Rhesus monkeys and humans include spontaneous recovery from 90% block: it is much faster in Rhesus monkey than humans. Taking these differences into account, the principles of the presented model will also hold in humans.
Regarding the safety of sugammadex, there were no significant effects on blood pressure or heart rate. Signs of residual or recurarization in these experiments were also not observed. In this study the half-life of sugammadex is relatively short (30 min) and the absence of recurarizations proves that the sugammadex-recoruronium complex is being eliminated just as fast or faster. As long as these time courses are relatively the same in humans, the monkey model is a good predictor for the effects of sugammadex in humans.
In conclusion, sugammadex is a promising fast and effective reversal agent for neuromuscular block induced by rocuronium, based on a new concept of chemical encapsulation, and without cardiovascular side effects.
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Although recurarization has not been observed, the half-life of sugammadex is relatively short in monkeys: 30 min. The mechanism of its action (encapsulation of rocuronium) and the short half-life suggest the possibility to perform rocuronium neuromuscular block after reversal of an earlier dose. 
